Before Josue Briceño even stepped into the batter’s box Thursday night, his performance had already taken on deeper meaning.

The Quick Draw water ride presents a classic amusement park dilemma: cool off and get soaked, or stay dry and slowly melt in ...

Beam Therapeutics (NASDAQ:BEAM) gains FDA orphan drug status for BEAM-101 to treat sickle cell disease. Read more here.

underscoring the therapy’s promise and the urgent need for effective AATD solutions. Preliminary data from ongoing Phase 1/2 trials show BEAM-302 is well tolerated and achieves dose-dependent ...

has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed ...

Here’s a look at the selected park design that could transform a vacant Water Street lot overlooking Exeter River.

With RMAT designation enabling closer and more frequent collaboration, we look forward to working with the FDA to accelerate the development of BEAM-302 and bring this potentially curative therapy to ...

Eric Morrow told his doctor about his family history of prostate cancer and asked if he needed testing. His doctor said no.

This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization ...